1. Academic Validation
  2. Antiviral Drugs in Influenza

Antiviral Drugs in Influenza

  • Int J Environ Res Public Health. 2022 Mar 4;19(5):3018. doi: 10.3390/ijerph19053018.
Magdalena Świerczyńska 1 Dagmara M Mirowska-Guzel 1 Edyta Pindelska 2
Affiliations

Affiliations

  • 1 Centre for Preclinical Research and Technology CePT, Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Banacha 1B, 02-097 Warsaw, Poland.
  • 2 Department of Analytical Chemistry and Biomaterials, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1B, 02-093 Warsaw, Poland.
Abstract

Flu is a serious health, medical, and economic problem, but no therapy is yet available that has satisfactory results and reduces the occurrence of these problems. Nearly 20 years after the registration of the previous therapy, baloxavir marboxil, a drug with a new mechanism of action, recently appeared on the market. This is a promising step in the fight against the Influenza Virus. This article presents the possibilities of using all available Antiviral drugs specific for influenza A and B. We compare all currently recommended anti-influenza medications, considering their mechanisms of action, administration, indications, target groups, effectiveness, and safety profiles. We demonstrate that baloxavir marboxil presents a similar safety and efficacy profile to those of drugs already used in the treatment of influenza. Further research on combination therapy is highly recommended and may have promising results.

Keywords

amantadine; baloxavir marboxil; influenza treatment; laninamivir; neuraminidase inhibitors; oseltamivir; peramivir; zanamivir.

Figures
Products